Skip to content

a Random, Double-blind, Double-simulation, Multicenter study of Chinese Herbal Compound Jinji Granules (CJG) for treatment Primary Premature Ejaculation: (Gan depression an Shen deficiency syndrome)

a Random, Double-blind, Double-simulation, Multicenter study of Chinese Herbal Compound Jinji Granules (CJG) for treatment Primary Premature Ejaculation: (Gan depression an Shen deficiency syndrome)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005688
Enrollment
Unknown
Registered
2022-03-09
Start date
2022-03-10
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ejaculation

Interventions

Experimental group:Compound Jinji Granules(CJG)+Dapoxetine simulator.CGJ is taken twice a day, one bag at a time, half an hour after breakfast and dinner, and after brewing with warm water. Dapoxetin
Control group:Dapoxetine+Compound Jinji Granules(CJG) simulation agent.CJG simulation agent is taken twice a day, one bag at a time, half an hour after breakfast and dinner, and after brewing with war

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
23 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1)Meet the diagnostic criteria of Western medicine for premature ejaculation; (2)Meet the standard of TCM syndrome differentiation. (3)The course of disease is more than 1 year. (4)23=age=50. (5)Sexual frequency=1 time/week, at least 6 times a month. (6)At least in the last 3 months and during the course of this study, the subject had stable marital relationship or stable adult female sexual partner. (7)Normal erectile function, IIEF-5 score > 21 [20-23]. (8)Subjects agree not to use any other drugs for premature ejaculation during the study period, including 5-HT inhibitors, Chinese herbal medicines (including decoction and proprietary Chinese medicine), or devices used for PE treatment. (9)Subjects (including partners) guarantee that they have no birth plan and voluntarily use appropriate contraceptive measures during the study period up to 3 months after the last medication. (10)The subject voluntarily signs the informed consent.

Exclusion criteria

Exclusion criteria: (1)Patients with urinary and reproductive tract infection, such as urethritis, prostatitis, etc.; (2)Patients with diabetes and neurological diseases; (3)Patients with cardiovascular diseases; (4)Patients with liver and kidney dysfunction; (5)Persons who abuse psychotropic drugs; (6)Patients with other sexual dysfunction; (7)Patients who are being treated with other drugs.

Design outcomes

Primary

MeasureTime frame
Intravaginal ejaculatory latency time(IELT);

Secondary

MeasureTime frame
Premature ejaculation Profile(PEP);Traditional Chinese medicine syndrome score;clinical global impression (CGI) of change;

Countries

China

Contacts

Public ContactWang Fu
fu311306@163.com13426071953

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026